ArticleAmerican journal of physiology. Renal physiology2013
Renoprotective effects of hepatocyte growth factor in the stenotic kidney.
Article in American journal of physiology. Renal physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Novel therapeutic strategies for renovascular disease.Current opinion in nephrology and hypertension · 2019Review
- A modified two-compartment model for measurement of renal function using dynamic contrast-enhanced computed tomography.PloS one · 2019Observational
- Emerging Paradigms in Chronic Kidney Ischemia.Hypertension (Dallas, Tex. : 1979) · 2018Review
- Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review.Journal of clinical and translational hepatology · 2018Review
- A translational model of chronic kidney disease in swine.American journal of physiology. Renal physiology · 2018Article
- Understanding and managing atherosclerotic renovascular disease: still a work in progress.F1000Research · 2018Review
- Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury.Hypertension (Dallas, Tex. : 1979) · 2017Review
- Role of the Renal Microcirculation in Progression of Chronic Kidney Injury in Obesity.American journal of nephrology · 2016Review
- Vascular Endothelial Growth Factor Therapy for the Kidney: Are We There Yet?Journal of the American Society of Nephrology : JASN · 2016Article
- Atherosclerotic renal artery stenosis: current status.Advances in chronic kidney disease · 2015Review
- Gained in translation: protective paradigms for the poststenotic kidney.Hypertension (Dallas, Tex. : 1979) · 2015Review
- Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015Article
- Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction.Biomaterials · 2015Article
- Article
- Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease.Kidney international · 2014Article
- Darkness at the end of the tunnel: poststenotic kidney injury.Physiology (Bethesda, Md.) · 2013Review
- Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?Journal of the American Society of Hypertension : JASHReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Renal microvascular (MV) damage and loss contribute to the progression of renal injury in renal artery stenosis (RAS). Hepatocyte growth factor (HGF) is a powerful angiogenic and antifibrotic cytokine that we showed to be decreased in the stenotic kidney. We hypothesized that renal HGF therapy will improve renal function mainly by protecting the renal microcirculation. Unilateral RAS was induced in 15 pigs. Six weeks later, single-kidney RBF and GFR were quantified in vivo using multidetector computed tomography (CT). Then, intrarenal rh-HGF or vehicle was randomly administered into the stenotic kidney (RAS, n = 8; RAS+HGF, n = 7). Pigs were observed for 4 additional weeks before CT studies were repeated. Renal MV density was quantified by 3D micro-CT ex vivo and histology, and expression of angiogenic and inflammatory factors, apoptosis, and fibrosis was determined. HGF therapy improved RBF and GFR compared with vehicle-treated pigs. This was accompanied by improved renal expression of angiogenic cytokines (VEGF, p-Akt) and tissue-healing promoters (SDF-1, CXCR4, MMP-9), reduced MV remodeling, apoptosis, and fibrosis, and attenuated renal inflammation. However, HGF therapy did not improve renal MV density, which was similarly reduced in RAS and RAS+HGF compared with controls. Using a clinically relevant animal model of RAS, we showed novel therapeutic effects of a targeted renal intervention. Our results show distinct actions on the existing renal microcirculation and promising renoprotective effects of HGF therapy in RAS. Furthermore, these effects imply plasticity of the stenotic kidney to recuperate its function and underscore the importance of MV integrity in the progression of renal injury in RAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.